ライフサイエンスコーパス: calcinosis

1 e of nephrocalcinosis and dystrophic cardiac calcinosis.

2 elop nephrocalcinosis and dystrophic cardiac calcinosis.

3 s performed to assess for acroosteolysis and calcinosis.

4 ating as well as decreasing the incidence of calcinosis.

5 lantation has also led to improvement of the calcinosis.

6 erosis and systemic lupus erythematosus with calcinosis.

7 nd 2 additional patients (4%) had persistent calcinosis.

8 s spectrum that includes an association with calcinosis.

9 leles was protective, for the development of calcinosis.

10 e MRI changes can precede the development of calcinosis.

11 frequently complicated by the development of calcinosis.

12 of SSc, including synovitis, tenosynovitis, calcinosis, acroosteolysis, and distal vascularization a

13 Dystrophic cardiac calcinosis, an age-related cardiomyopathy that occurs am

14 distal vascularization and is sensitive for calcinosis and acroosteolysis detection.

15 quency of US features, sensitivity of US for calcinosis and acroosteolysis, and respective confidence

16 An association between calcinosis and both interstitial lung disease and anti-M

17 chanism may underlie the development of both calcinosis and fingertip ulcers in patients with DM.

18 ndicitis was missed at US, whereas medullary calcinosis and myelolipoma were missed at CT.

19 0, which appears to have an association with calcinosis and p155 with lipodystrophy), cytokine polymo

20 es such as arthroplasty, excision of painful calcinosis, and digital sympathectomy have been employed

21 capsular hematoma, cholelithiasis, medullary calcinosis, and myelolipoma.

22 JDM or for developing complications such as calcinosis, and the clinical findings of persistent nail

23 Other extramuscular manifestations, such as calcinosis, are particularly difficult to treat, and stu

24 utaneous edema developed clinically apparent calcinosis at the same location within 9 months.

25 Many agents have been used for treatment of calcinosis but none has been accepted as a standard ther

26 a 12-year history of SLE who presented with calcinosis cutis at the time of SLE diagnosis developed

27 Recent data on therapy for calcinosis cutis highlights that more prospective studie

28 Calcinosis cutis is common in several connective tissue

29 It is characterized by calcinosis cutis, Raynaud's phenomenon, esophageal invol

30 Clinical features of the CREST (calcinosis cutis, Raynaud's syndrome, esophageal dysmoti

31 s well as the proposed medical therapies for calcinosis cutis.

32 Dystrophic cardiac calcinosis (DCC) occurs in certain inbred strains of mic

33 Calcinosis, defined as the presence of calcium depositio

34 Additional outcome measures were onset of calcinosis, effect of treatment on height, and complicat

35 Patients with vs those without calcinosis had a longer disease duration (median, 6.9 ye

36 mperfecta), mineralization (familial tumoral calcinosis/hyperostosis hyperphosphatemia syndrome, hypo

37 Risk factors for calcinosis in adults with DM have not been extensively s

38 sease duration were strongly associated with calcinosis in all multivariate models, independent of th

39 genetic loci determining dystrophic cardiac calcinosis in an F2 intercross of resistant C57BL/6J and

40 scuss the most recently published data about calcinosis in connective-tissue diseases with emphasis o

41 An exception is identifying calcinosis in patients with myositis; there is some evid

42 and is associated with an increased risk of calcinosis in young patients.

43 PURPOSE OF REVIEW: Calcinosis is a recognized manifestation of many connect

44 Familial tumoral calcinosis is characterized by ectopic calcifications an

45 RECENT FINDINGS: Calcinosis is more common in patients with sustained dis

46 Our data suggest that calcinosis is positively associated with longer disease

47 Normophosphatemic familial tumoral calcinosis (NFTC) is caused by mutations in the SAMD9 ge

48 Autoantibodies to NXP-2 were associated with calcinosis (odds ratio, 15.52; 95% CI, 2.01-119.90), whe

49 tissues, as exemplified by familial tumoral calcinosis, pseudoxanthoma elasticum, generalized arteri

50 iffer by altering collagen or through medial calcinosis, raise the blood pressure, increase shearing

51 th diffuse and limited scleroderma or CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility,

52 CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction

53 Sera from patients with diffuse SSc, calcinosis, Raynaud's, esophageal dysmotility, sclerodac

54 ars, digital-tip ulcers, telangiectasia, and calcinosis than those with ssSSc, in part related to inc

55 Calcinosis was a relatively uncommon clinical feature in

56 Calcinosis was found in 17 patients (39%) with US, with

57 h anti-p140 antibodies, the association with calcinosis was significant compared with the rest of the

58 persistent weakness, muscle dysfunction, and calcinosis were most frequent (23-30%) at the last evalu

59 20% of adults with dermatomyositis (DM) have calcinosis, which can lead to significant morbidity.

60 r-old girl who presented with severe tumoral calcinosis with dural and carotid artery calcifications.

61 e primarily aimed at treating the process of calcinosis with varying success.

62 Fourteen patients (11.1%) had calcinosis, with the extremities most commonly involved.